BrainScope has launched its next-generation deep learning platform that will enhance its ability to deliver fast, objective, and clinically actionable insights across brain health conditions including concussion, stroke, and early Alzheimer’s detection.

BrainScope developed and has commercialized the first U.S. Food and Drug Administration-cleared AI/machine learning medical device in neurology. The integration of deep learning into BrainScope’s proprietary platform marks a major leap forward in automated EEG analysis.

BrainScope’s new Large Neural Model platform brings many of the breakthroughs of Large Language Models (LLMs) to bear on EEG data, eliminating the need for specialized qEEG interpretation. This proprietary approach enhances BrainScope’s first-in-class machine learning foundation, with the potential to significantly expand its utility across clinical care, research, and biopharma by enabling the development of more refined biomarkers to support precision-driven clinical trial recruitment, early diagnosis, personalized treatment, and improved patient outcomes.

To help guide the company as it expands its clinical program and commercial activities, BrainScope has announced key updates to its Board of Directors. Ralph Terkowitz, who has served on BrainScope’s Board since 2023, has been elected chairman. A former general partner at ABS Capital Partners, Terkowitz brings decades of experience helping technology companies grow and scale. He also serves on the board of The 10,000 Brains Project and is co-chairman of The Robert Packard Center for ALS Research at Johns Hopkins. In his expanded role, Terkowitz will guide BrainScope’s continued growth and adoption of its AI-powered brain health platform.

“It’s exciting to take on the role of chairman at such a transformative time,” Terkowitz stated. “BrainScope is turning groundbreaking science into meaningful real-world impact, and has demonstrated success in using qEEG coupled with computational neuroscience as a diagnostic tool to aid in assessment of many neurological conditions including stroke, concussions, and early Alzheimer’s. I look forward to helping the team expand this potentially groundbreaking opportunity.”

Also joining the Board are Mike Genau, a seasoned global medtech executive and former president of Medtronic’s Americas Region, and Brian Shea, who oversees healthcare investments and deal origination as Head of Origination at Aon Advantage Funds. Genau led a $7 billion business unit at Medtronic and brings deep expertise in scaling medical technologies and guiding commercial strategy. Shea offers a valuable perspective at the intersection of finance, healthcare, and technology.

“We’re thrilled to elevate Ralph to the chairman role and honored to welcome Mike and Brian to our board during this pivotal moment in BrainScope’s evolution,” BrainScope CEO Laurie Silver said. “Ralph has been an invaluable advisor as we’ve developed and launched our next-generation EEG-based Large Neural Model platform. Mike’s leadership in medtech and Brian’s strategic investment insight will be beneficial as we scale commercially, drive clinical innovation in expanded markets, and bring in new investment partners. To reflect our expanded capabilities, we’ve also launched a new website showcasing our deep learning technology and broader brain health mission.”

BrainScope is a neurotechnology company with more than 15 years of experience advancing brain health through objective, AI-powered insights derived from brain electrical activity (EEG). Its proprietary platform analyzes EEG data from any source using advanced machine and deep learning to deliver rapid, radiation-free, accessible and cost-effective biomarkers, greatly expanding the clinical utility of traditional EEG. BrainScope’s initial commercial product remains the only point-of-care technology that objectively assesses head-injured patients for both brain bleeds and concussions. The company is now advancing novel biomarkers for early Alzheimer’s detection, ARIA assessment, rapid stroke evaluation, concussion subtyping, military blast exposure, and brain fog.